
Biotech & Health
Cognito Alzheimer’s Trial Misses Primary Endpoint
Cognito’s Phase 3 HOPE study missed its primary endpoint. Findings in a prespecified mild-disease subgroup suggest possible benefit, but Spectris AD remains investigational as the company prepares for FDA discussions.